The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

Frontiers in Immunology

Ignacio Heras-Murillo¹  Carlos del Fresno²  Mariano Esteban³  Juan García-Arriaza³  David Sancho³  Pablo Gastaminza³  Paola Brandi⁴  Andrés López-Perrote⁴  Natalia Vicente⁴  Joaquín Amores-Iniesta⁴  Urtzi Garaigorta⁴  Maria Rosaria Pricolo⁴  Carmen Suay-Corredera⁴  Aitor Jarit-Cabanillas⁴  Gillian Dunphy⁴  Sarai Martínez-Cano⁵  Sofía Cabezudo⁶  Jorge Alegre-Cebollada⁶  Oscar Llorca⁶  Ana González-Corpas⁶ 

[1] D Department, Inmunotek S.L., Alcalá de Henares, Spain;Department of Infectious Diseases and Immunity, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain;Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain;Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain;;R&Structural Biology Department, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain;

关键词: innate immunity;    viral infections;    polybacterial mucosal immunotherapy;    SARS-CoV-2;    vaccine immunogenicity;   

DOI  :  10.3389/fimmu.2021.748103

来源: DOAJ

【 摘 要 】

COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.

【 授权许可】

Unknown